Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma

Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma

Abstract Background Nivolumab, an anti-programmed cell death-1 monoclonal antibody, has improved the survival of patients with malignant melanoma. Despite its efficacy, nivolumab inconsistently induces thyroid dysfunction as an immune-related adverse event (irAE). This study aimed to evaluate nivolu...

Full description

Bibliographic Details
Main Authors: Seiichi Yano, Kenji Ashida, Hiromi Nagata, Kenji Ohe, Naoko Wada, Yukina Takeichi, Yuki Hanada, Yuta Ibayashi, Lixiang Wang, Shohei Sakamoto, Ryuichi Sakamoto, Hiroshi Uchi, Motoaki Shiratsuchi, Masutaka Furue, Masatoshi Nomura, Yoshihiro Ogawa
Format: Article
Language:English
Published: BMC 2018-06-01
Series:BMC Endocrine Disorders
Subjects:
Thyroid
Nivolumab
Thyroiditis
Hypothyroidism
Programmed cell death − 1
Online Access:http://link.springer.com/article/10.1186/s12902-018-0267-x

Internet

http://link.springer.com/article/10.1186/s12902-018-0267-x

Similar Items